Physician
Donna M O'neill M.D. P.C.
Donna M O'neill M.D. P.C. was paid $1.07M by Medicaid between Jan 2018 and Nov 2024, across 16 billing codes. Its largest line is J0741, Injection, cabotegravir and rilpivirine, 2mg/3mg — 49% of everything it billed.
33Billing provider infoDONNA M O'NEILL M.D. P.C.
JACKSON, MI 49201
JACKSON, MI 49201
33aNPI1770796567assigned 05/08/2007
33bProvider typeInfectious Disease Physician
28Total paid$1.07M
24GClaims18,178
24DCodes billed16
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Infectious Disease Physician providers in Michigan
Rank by total paid#6 of 43
Median peer was paid$278K
This provider vs. median3.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,113 | $82K | |
| 2019 | 3,048 | $83K | |
| 2020 | 2,828 | $80K | |
| 2021 | 3,193 | $123K | |
| 2022 | 2,419 | $66K | |
| 2023 | 2,232 | $464K | |
| 2024incomplete | 1,345 | $172K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J0741 | Injection, cabotegravir and rilpivirine, 2mg/3mg | 49% | 126 | 117 | $521K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 18% | 8,398 | 1,753 | $196K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 12% | 3,374 | 2,197 | $123K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 11% | 2,455 | 1,764 | $123K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | 2.5% | 67 | 67 | $26K |
| 96367 | 2.1% | 2,366 | 757 | $23K | |
| 99222 | Initial hospital care, per day, moderate complexity | 2.1% | 306 | 300 | $22K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 1.3% | 33 | 33 | $14K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 20 | 20 | $8K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 130 | 130 | $5K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 478 | 312 | $4K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 253 | 234 | $3K |
4 more codes
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 28 | $1K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 15 | $885.46 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 71 | $499.80 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 58 | $10.53 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJOHNSON, PEGGY (OFFICE MANAGER)